News release. BridgeBio Pharma, Inc. September 10, 2024. Accessed September 16, 2024. https://bridgebio.com/news/bridgebio-pharma-reports-topline-results-from-phase-1-2-trial-of-investigational-gene-therapy-for-congenital-adrenal-hyperplasia-cah/ 2. The Pipeline. BridgeBio Pharma, Inc. Website. Accessed September 16, 2024. https://bridgebio.com/pipeline/#pipeline 3. BridgeBio receives FDA's regenerative medicine advanced therapy (RMAT) designation for BBP-812 Canavan disease gene therapy program. News release. BridgeBio Pharma, Inc. September 10, 2024. Accessed September 16, 2024. https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-receives-fdas-regenerative-medicine-advanced-therapy